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1. Introduction
In chronic conditions, the World Health Organiza-
tion (WHO) considers it essential to maximize the 
patients’ willingness to co-operate with therapies; 
and it classified the factors influencing adherence 
into 5 dimensions. The study was made in 2003 
and it is still regarded as a standard document by 
researchers studying patient adherence. With re-
gards to the ever aging societies, like Hungary, 
needs to highlight the prevalence and the inci-
dence of the chronic disorders. [1]. Among chronic 
conditions, diseases affecting the musculoskeletal 
system are on the rise; besides the basic disease, 
these cause several other diseases, loss of quality 
of life, loss of working capacity on the labour mar-
ket, etc., and thus they put an increasing burden 
on the patients concerned and on the society both 
regarding quality of life and in economic terms. 
The importance and the severity of the issue 
were recognized worldwide and the ‘Decade of 
Bones and Joints’ was proclaimed in 2000, which 
was extended until 2020 due to its success, and 
several other European organizations have also 
taken steps to focus attention on the disease [2-4]. 
Hungary was the first to join the program on state 
level and achieved major success in many areas [5, 
6]. In spite of all these efforts, very few Hungarian 
studies have been made and published on OA 
(erosion of articular cartilage).
Arthrosis is the leading cause of disability and 
pain all over the world and was ranked as the 6th 
most common cause of disability in 2003, estimat-
ed to be the 4th in rank in 2020 [7-9]. In Hungary, 
the number of patients affected can only be esti-
mated; during the European Health Interview Sur-
vey of 2014, 17% of the people asked were found 
to have arthrosis-related joint pain, which can 
mean the involvement of about ~ 1,600,000 people 
nationwide [10].
The measurement of the quality of life and ad-
herence of patients suffering from OA is compli-
cated by several factors, which are the following: 
 − The disease is usually diagnosed when it is al-
ready in an advanced stage, i.e. when there are 
severe symptoms. The therapeutic options are 
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limited; what can be achieved is mainly the al-
leviation of the symptoms for a longer or short-
er period of time [11-13].
 − As opposed to other musculoskeletal disorders, 
no well-proved disease-modifying active ingre-
dient is available [14, 15].
 − Due to the complex nature of the disease, the 
patient’s active and conscious cooperation with 
the healthcare professionals involved in the 
treatment is essential.
The therapy is described in the NICE guideline 
[16], which divides the tasks into three separate 
parts. The first and foremost is the education of 
patients during treatment, both by doctors and 
pharmacists, which includes the promotion of a 
healthy lifestyle, the incorporation of sports into 
everyday life, i.e. health-conscious behavior; and 
also adopting the so-called Mediterranean diet 
[17]. All these reduce the risk of the most impor-
tant risk factor, obesity, as well as the develop-
ment or worsening of cardiovascular diseases, di-
abetes mellitus and mental illnesses, which are 
also risk factors in the incidence of OA.
Another element of therapy is the use of non-
pharmacological therapies, which include electri-
cal impulse therapies, manual therapies and balne-
ological therapies. Currently, these provide the 
longest asymptomatic period. Paracetamol and 
non-steroidal anti-inflammatory drugs (NSAIDs), 
usually applied topically then orally, are the drugs 
of first choice in medicated therapies. If they fail to 
be effective, the administration of the opioid anal-
gesic tramadol is recommended. Most of the active 
ingredients mentioned in the first group are also 
available in drugs without a prescription, so the 
extent of their use cannot be measured in this dis-
ease; it is well-known that their excessive and com-
bined use generates several adverse effects and 
causes additional burdens.
The protocol does not recommend the use of 
chondroprotective drugs, although patients often 
expect these “miracle drugs” to rebuild cartilage. 
Commercially available products are available to 
users through a number of distribution chains, fre-
quently bypassing healthcare professionals; this 
can result in uncontrolled use if communication be-
tween the parties is inadequate during patient care. 
The rational use of the great number of over-
the-counter drugs and chondroprotective prepara-
tions can be controlled only by the pharmacist, 
who can provide information to the family doctor 
and to the specialist, and can also recommend the 
patient to visit the doctor.
On the other hand, physicians and physiothera-
pists can inform the pharmacist about the pa-
tients’ medical history, who can then dispense the 
medication with this knowledge. 
In the light of all these facts, it can be hypothe-
Figure 1 Division of the population in question by age and gender
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sized that adherence can 
be improved if OA pa-
tients’ burdens affecting 
therapeutic cooperation 
are explored. With the im-
provement of adherence, 
patient satisfaction and 
cooperation with therapy 
improves, which in turn 
has a favourable influence 
on specific parameters of 
quality of life, resulting in 
improvements at individ-
ual, family and social lev-
els. Given the complexity 
of the therapy, this can be 
achieved only through the 
collaboration of the healthcare professionals par-
ticipating in the treatment, which will improve 
therapeutic efficiency. Therefore, the aim of this 
survey is to explore the most common causes in 
order to identify potential intervention points 
based on the 5 dimensions of adherence of the 
WHO. The causal (Ishikawa) diagram (Figure 1) 
made on the basis of literature research illustrates 
the factors that influence the quality of life and co-
operation of arthritic patients, which, at the same 
time, can also be the most important intervention 
points for improving the therapeutic outcome.  
2. Methods
As the first step, the affected population was as-
sessed retrospectively, in the course of which the 
data of patients treated by the Bács-Kiskun Coun-
ty Teaching Hospital of the University of Szeged, 
the Musculoskeletal Rehabilitation Unit of the Es-
tablishment in Kiskunfélegyháza was processed. 
During the data collection period we randomly 
selected five anonymised patient discharge re-
ports 
Documents from the period of 2007-2013 were 
selected for the study; the inclusion criterion was 
the diagnosis of lower limb OA.
Assessment aspects:
 − gender
 − age
 − body mass index (BMI)
 − residence,
 − average of nursing days,
 − non-pharmacological therapies received during 
hospitalization, medicines received,
 − existing co-morbidities.
Statistical evaluation was performed with Mi-
crosoft Excel 2013 and Version 23 of the SPSS pro-
gram package.
The study was conducted with the permission 
of the Scientific and Research Ethics Committee, 
file number: 24950-3/2016/EKU.
3. Results
3.1. Gender and age of patients
A total of 400 final reports were evaluated during 
the study period. The majority of cases (69%) were 
female with an average age of 72 years (Table I). It 
can be seen that the majority of patients were in 
the age group 76-85 for women and 66-75 for men 
(Figure 2). This result is not surprising as the num-
ber of patients who visit a healthcare institution 
Table I Descriptive statistics regarding to age
Aspects Values
Number of 
patients (N)
Valid 400
Missing    0
Mean       72.10
Median       74.00
Std. Deviation       10.81
Minimum       45.00
Maximum       93.00
Table interpretation: 
 − N: sample size
 − Valid: Actual number of sample size
 − Missing: Missing number of sample
 − Mean: Average age based on the evaulated sample 
 − Median: Median of the age based on the evaulated sample
 − Standard Deviation (Std. Deviation): Dispersion of the age of the 
examined sample around the mean age
 − Minimum: The lowest age in the sample tested
 − Maximum: The highest age in the sample tested
Figure 2 Cause and effects relationships between factors influencing osteoarthrosis
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with complaints increases dramatically over the 
age of 60. As regards age analysis, it should be 
noted that 128 patients (32%) were under 65 years 
of age, i.e. in active working age. Considering that 
the average of nursing days for the sample exam-
ined was 18.6 days, this means that the affected 
persons were unable to work and to perform their 
duties minimum for this period. There was no sig-
nificant relationship (p = 0.075, NS) between gen-
der and age at significance level 0.05 
3.2. Relationship of body mass index (BMI) with 
gender and age
The most important risk factor for arthrosis is 
overweight. Inadequate body mass puts enormous 
strain on the joints and cartilage, which are erod-
ed continuously during daily activities; and this 
can be further aggravated by the lack of sports ac-
tivities in the daily routine.
From among the 400 cases examined, the data 
necessary for BMI calculation (body weight and 
height) were available in 224 cases. The results are 
summarized in Figure 3 ~ 46% of the patients were 
found to be in the most severe “obese” category; 
overall, ~ 80% of the cases deviated from the “nor-
mal” body weight category (BMI categories, based 
on the classification of the WHO). There was no sig-
nificant difference between men and women (p = 
0.148). Such a serious weight problem not only en-
hances the development and progression of muscu-
loskeletal disorders but also forms the basis of many 
other chronic conditions, which increase the likeli-
hood and frequency of hospitalization as well as the 
number and quantity of medications taken.
3.3. Hungarian data related to 
the recommendations of the 
NICE disease-specific guideline
Today the treatment of ar-
throsis is primarily limited 
to relieving symptoms; the 
reason for this is that al-
though the development of 
therapies for the modifica-
tion of the course of the dis-
ease is researched exten-
sively Currently there is no 
active ingredient available 
with an adequate level of 
evidence and the treatment 
related risk is still higher 
than the therapeutic benefit 
For the sake of completeness, it should be noted 
that patient education recommended in the first 
place is going to be the subject of the following 
study; no data regarding it were available in the 
current retrospective survey.
3.4. Non-pharmacological therapy
The guideline identifies non-pharmacological ther-
apeutic options as the level following patient edu-
cation. These treatments can be received in the re-
habilitation centers operating in healthcare institu-
tions or in qualified spas, with a specialist’s refer-
ral. As the studied population underwent muscu-
loskeletal rehabilitation treatment, our study also 
included the evaluation of non-pharmacological 
treatments received during hospitalization. The 
guideline groups therapies according to their focus 
on muscle strengthening, gymnastic exercises or 
the use of electrical impulse. We grouped the sur-
vey data according to this, and if they did not spe-
cifically belong to any of the groups, they were 
classified into the so-called “other” category. The 
results are shown in Figure 4.
Gymnastic exercises included individual and 
group exercises performed on land and in water, 
with or without help (striped marking). Mobiliza-
tion, weight bath and medicinal bath were 
grouped into the category of muscle strengthen-
ing (black marking); while treatments based on 
electrical impulse included Tangentor, galvanic 
treatment, iontophoresis, TENS and the use of BE-
MER mattress (checkered marking). Ultrasound 
and mud pack were classified in the “other” cate-
gory (grey marking).
Figure 3 Division of the population in question by Body Mass Index BMI categories in 
accordance with WHO classification : <18.5 underweight, 18.51 – 24.9 normal, 25.0 
-29.99 overweight, >30.0 obese
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Non-pharmacological therapies were very di-
verse, all the options in modern medicine were 
available for the patients. The percentage distribu-
tion of the treatments shows that the rates of gym-
nastic exercises and massage were the highest. Pa-
tients received these in ~ 60% and ~ 70% of the 
cases. When discharged, the patients were recom-
mended to continue gymnastic exercises at home 
on a daily basis; the nature of the exercises was 
such that after training the patients could perform 
them on their own, without continuous expert su-
pervision. Needless to 
say, their regular perfor-
mance requires a high de-
gree of patient adherence.
3.5. Evaluation of pharma-
cological therapy
As already mentioned in 
the introduction, the 
NICE guideline recom-
mends the use of para-
cetamol and the topical 
application of non-steroi-
dal anti-inflammatory 
drugs (NSAIDs) as first-line agents; followed by 
oral NSAIDs as the next step, and finally weak 
opiates (tramadol and its derivatives); the latter is 
frequently the first-line therapy for the elderly. 
Given that paracetamol and the vast majority of 
NSAID formulations are available without a medi-
cal prescription and the diagnosis is not estab-
lished, the proportion of formulations purchased 
specifically for musculoskeletal complaints cannot 
be determined without a special questionnaire 
survey. Furthermore, the evaluation is limited by 
the fact that this active ingredient group includes 
hundreds of active ingredients and there is no 
clear recommendation for a particular one. Selec-
tive inhibitors for cyclooxygenase type 2 enzyme 
are mostly prescription-only preparations and can 
thus be monitored. It must be mentioned that their 
excessive or unjustified use may result in cardio-
vascular complaints.
The active ingredient diclofenac, which is not 
selective for the enzyme type, is also the active in-
gredient in a great number of preparations for 
musculoskeletal complaints; in this case, many 
non-prescription drugs are available, and their use 
for this purpose cannot be assessed without a spe-
cial survey. It should be noted here that the pro-
longed and combined use of non-selective 
NSAIDs may result in the development of severe 
gastrointestinal adverse effects or in the exacerba-
tion of the existing symptoms; patient education is 
essential in this stage as well.
Based on the final discharge reports, , a total of 
3,313 drugs were administered to 400 patients, 
which means an average of ~ 8 drugs per patient. 
Recorded NSAIDs, formulations containing 
paracetamol and tramadol were included in the 
evaluation; and also proton pump inhibitors, 
which the recommendation strongly recommends 
Figure 4 Percentage distribution of non-pharmacological therapies during the study period
Figure 5 Frequency of the pharmacons according to 
relevance with the disorder in question
Distribution of the used pharmacons according to ATC 
categories
 − A02B: Drugs for peptic ulcer and gastro-oesophageal 
reflux disease (GORD)
 − M01-02-03 Anti-inflammatory and antirheumatic 
products, Topical products for joint and muscular pain, 
Muscle relaxants
 − N02: Analgesics
Regarding to the Figure is demonstrated the number 
of medicine boxes diveded by years. The pharmacons 
were counted based on the patients documentation. The 
mentioned ATC categories (A02B, M01-02-03, N02) were 
selected in accordance with NICE guideline therapeutic 
suggestion. 
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for use with NSAIDs. The drugs used were ana-
lyzed with the consideration of the ATC codes of 
the active ingredients, the results are summarized 
in Figure 5.
It is noteworthy that first-line paracetamol was 
mentioned only in 11 cases, while tramadol and 
its derivatives were taken in 168 cases (group 
NO2), which had been expected considering the 
age distribution (grey line). Another important 
finding is that despite taking a great amount of 
non-steroids, the number of gastric protectors is 
negligible (NSAID – black line, PPI – proton pump 
inhibitors – broken line). The curves of non-ste-
roids and PPIs run essentially parallel to each oth-
er in the period studied, which suggests that in 
some cases PPI was used while taking NSAIDs, 
but generally only in one third of the cases.
3.6. Existing co-morbidities 
Existing co-morbidities were also recorded in the 
patients’ final reports and their evaluation is 
shown in Figure 6. According to the data, the diag-
nosis contained “other musculoskeletal com-
plaint” almost without exception, which means 
379 cases (grey dots). Some cardiovascular disease 
occurred in 70-80% of the cases in the test sample 
(black stripes). DM was also present consistently 
each year with an incidence of 20-30% (black 
marking), and the basic disease was accompanied 
by mental/psychological problems in many cases 
(broken lines).
4. Discussion
In conclusion, as a result of aging societies, arthro-
sis will result in an increasing number of patients 
worldwide, thus in Hungary as well. The situation 
may be worsened by low health literacy, the gen-
eral lack of health-conscious behavior, and un-
healthy and sedentary lifestyles, which are com-
mon problems in today’s societies.
It is a particularly great challenge to make the 
diagnosis in time as the disease is “silent” for a 
while; pain and impaired mobility that interfere 
with daily activities occur only in the advanced 
stage of the disease. By this time, arthrosis is of 
such extent that the affected population needs 
continuous treatment.
The knowledge of the factors leading to the de-
velopment of arthrosis and the analysis of the 
available patient documentation are absolutely 
necessary to establish the Hungarian population’s 
state and, on the basis of the facts, to explore po-
tential intervention points in order to improve the 
patients’ quality of life.
The current survey, based on the international 
guideline, processes and evaluates data from a 
representative sample of Hungarian patients, in 
the groups of the recommended therapies, broken 
down according to non-pharmacological and 
pharmacological therapies.
A significant proportion of the Hungarian pa-
tient population selected by randomized sampling 
is in active working age, and the majority of them 
belong to the overweight or obese categories.
Non-pharmacological rehabilitation treatments 
are widespread, they are efficient and result in a 
long-term asymptomatic period; however, the pa-
tients discharged from the treatment have to do 
the exercises recommended by doctors and phys-
iotherapists on their own at home every day in or-
der to maintain the achieved results, so the pa-
tients’ conscious adherence is essential.
Pharmacological therapy is characterized main-
ly by the use of over-the-counter preparations, 
which the patients commonly take in excess and 
in combination, parallel to their prescription-only 
counterparts. This phenomenon may induce ad-
verse effects, the development or worsening of co-
morbidities. Irrespective of this, co-morbidities af-
fecting the cardiovascular and metabolic systems 
are more common in arthrosis, which was high-
lighted in our study.
5. Conclusion
In order to comply with the guideline on patient 
education, the multidisciplinary collaboration of 
Hungarian healthcare professionals working in 
different areas is required. Besides family doctors, 
Figure 6 Incidence of co-morbidities during the period 
studied
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specialists and physiotherapists, pharmacists also 
have a prominent role due to the phenomena ex-
perienced in pharmacological therapy. Pharma-
cists taking part in the practice, in collaboration 
with dietitian and physiotherapist colleagues, can 
ensure mutual and ongoing communication by 
providing relevant information to the doctor re-
sponsible for therapy. In this way, patient care is 
shared by professionals with appropriate compe-
tences, the excessive use of unnecessary drugs 
taken on the patient’s own initiative can be avoid-
ed, the monitoring of recommendations for life-
style and exercises at home can be shared, and ad-
herence can be maintained longer. The simultane-
ous and combined use of all these, the collabora-
tion of healthcare professionals is the key to suc-
cessful therapeutic outcome and the resulting 
improvement in the quality of life in the case of 
osteoarthrosis as well.
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